Iontophoresis of vidarabine monophosphate for herpes orolabialis

Louis P. Gangarosa; James M. Hill; Barry L. Thompson; Carol Leggett; J. Peter Kissing

doi:10.1093/infdis/154.6.930

Iontophoresis of vidarabine monophosphate for herpes orolabialis

Louis P. Gangarosa, James M. Hill, Barry L. Thompson, Carol Leggett, J. Peter Kissing

Infectious Disease

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

The cutaneous application of antiviral agents was studied by iontophoresis, a process that increases penetration of most drugs 20- to 60-fold. Twenty-seven subjects with vesicular orolabial herpes were treated one time in a double-blind, placebo-controlled clinical study: nine received vidarabine monophosphate (ara-AMP), nine received acyclovir (ACV), and nine received NaCl. Ara-AMP-treated lesions yielded lower titers of virus after 24 hr compared with lesions treated with NaCl or ACV (P < .05) and time to dry crust (P < .05) compared with the other two agents. There was a trend toward decreased healing time after ara-AMP treatment.

Original language	English (US)
Pages (from-to)	930-934
Number of pages	5
Journal	Journal of Infectious Diseases
Volume	154
Issue number	6
DOIs	https://doi.org/10.1093/infdis/154.6.930
State	Published - 1986

ASJC Scopus subject areas

Immunology and Allergy
Infectious Diseases

Access to Document

10.1093/infdis/154.6.930

Fingerprint Dive into the research topics of 'Iontophoresis of vidarabine monophosphate for herpes orolabialis'. Together they form a unique fingerprint.

Cite this

@article{5c72f3c328324c5bbd891d035fe7c96c,

title = "Iontophoresis of vidarabine monophosphate for herpes orolabialis",

abstract = "The cutaneous application of antiviral agents was studied by iontophoresis, a process that increases penetration of most drugs 20- to 60-fold. Twenty-seven subjects with vesicular orolabial herpes were treated one time in a double-blind, placebo-controlled clinical study: nine received vidarabine monophosphate (ara-AMP), nine received acyclovir (ACV), and nine received NaCl. Ara-AMP-treated lesions yielded lower titers of virus after 24 hr compared with lesions treated with NaCl or ACV (P < .05) and time to dry crust (P < .05) compared with the other two agents. There was a trend toward decreased healing time after ara-AMP treatment.",

author = "Gangarosa, {Louis P.} and Hill, {James M.} and Thompson, {Barry L.} and Carol Leggett and {Peter Kissing}, J.",

year = "1986",

doi = "10.1093/infdis/154.6.930",

language = "English (US)",

volume = "154",

pages = "930--934",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "6",

}

TY - JOUR

T1 - Iontophoresis of vidarabine monophosphate for herpes orolabialis

AU - Gangarosa, Louis P.

AU - Hill, James M.

AU - Thompson, Barry L.

AU - Leggett, Carol

AU - Peter Kissing, J.

PY - 1986

Y1 - 1986

N2 - The cutaneous application of antiviral agents was studied by iontophoresis, a process that increases penetration of most drugs 20- to 60-fold. Twenty-seven subjects with vesicular orolabial herpes were treated one time in a double-blind, placebo-controlled clinical study: nine received vidarabine monophosphate (ara-AMP), nine received acyclovir (ACV), and nine received NaCl. Ara-AMP-treated lesions yielded lower titers of virus after 24 hr compared with lesions treated with NaCl or ACV (P < .05) and time to dry crust (P < .05) compared with the other two agents. There was a trend toward decreased healing time after ara-AMP treatment.

AB - The cutaneous application of antiviral agents was studied by iontophoresis, a process that increases penetration of most drugs 20- to 60-fold. Twenty-seven subjects with vesicular orolabial herpes were treated one time in a double-blind, placebo-controlled clinical study: nine received vidarabine monophosphate (ara-AMP), nine received acyclovir (ACV), and nine received NaCl. Ara-AMP-treated lesions yielded lower titers of virus after 24 hr compared with lesions treated with NaCl or ACV (P < .05) and time to dry crust (P < .05) compared with the other two agents. There was a trend toward decreased healing time after ara-AMP treatment.

UR - http://www.scopus.com/inward/record.url?scp=0023020053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023020053&partnerID=8YFLogxK

U2 - 10.1093/infdis/154.6.930

DO - 10.1093/infdis/154.6.930

M3 - Article

C2 - 2431074

AN - SCOPUS:0023020053

VL - 154

SP - 930

EP - 934

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 6

ER -